Bendamustine

Bendamustine is a bifunctional alkylating agent used for the treatment of chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and multiple myeloma. It combines the alkylating properties of nitrogen mustard with a purine-like benzimidazole ring. Mediocon Inc supplies pharmaceutical-grade Bendamustine meeting IP/BP/EP/USP standards.

Key Features

• Bifunctional alkylating agent
• IP/BP/EP/USP compliant quality
• Treatment for CLL, NHL, and multiple myeloma
• Suitable for IV infusion formulations

Applications

• Chronic lymphocytic leukemia
• Non-Hodgkin lymphoma treatment
• Multiple myeloma therapy
• Oncology IV formulations

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings